Estabrook Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $169K | Buy |
1,216
+16
| +1% | +$2.24K | 0.02% | 126 |
|
|
2025
Q4 | $147K | Hold |
1,200
| – | – | 0.02% | 133 |
|
|
2025
Q3 | $133K | Hold |
1,200
| – | – | 0.02% | 138 |
|
|
2025
Q2 | $133K | Hold |
1,200
| – | – | 0.02% | 136 |
|
|
2025
Q1 | $134K | Hold |
1,200
| – | – | 0.02% | 134 |
|
|
2024
Q4 | $111K | Hold |
1,200
| – | – | 0.02% | 148 |
|
|
2024
Q3 | $101K | Hold |
1,200
| – | – | 0.02% | 164 |
|
|
2024
Q2 | $82.3K | Hold |
1,200
| – | – | 0.01% | 174 |
|
|
2024
Q1 | $87.9K | Hold |
1,200
| – | – | 0.01% | 167 |
|
|
2023
Q4 | $97.2K | Hold |
1,200
| – | – | 0.02% | 163 |
|
|
2023
Q3 | $89.9K | Hold |
1,200
| – | – | 0.02% | 167 |
|
|
2023
Q2 | $92.5K | Hold |
1,200
| – | – | 0.02% | 174 |
|
|
2023
Q1 | $99.6K | Hold |
1,200
| – | – | 0.02% | 171 |
|
|
2022
Q4 | $103K | Hold |
1,200
| – | – | 0.02% | 168 |
|
|
2022
Q3 | $74K | Hold |
1,200
| – | – | 0.01% | 181 |
|
|
2022
Q2 | $74.2K | Hold |
1,200
| – | – | 0.01% | 189 |
|
|
2022
Q1 | $71.3K | Hold |
1,200
| – | – | 0.01% | 199 |
|
|
2021
Q4 | $87.1K | Buy |
+1,200
| New | +$82.7K | 0.01% | 192 |
|
|
2017
Q3 | – | Sell |
-350
| Closed | -$24.8K | – | 402 |
|
|
2017
Q2 | $24.8K | Sell |
350
-3,290
| -90% | -$219K | ﹤0.01% | 289 |
|
|
2017
Q1 | $247K | Sell |
3,640
-300
| -8% | -$21.1K | 0.04% | 128 |
|
|
2016
Q4 | $282K | Sell |
3,940
-1,655
| -30% | -$123K | 0.04% | 122 |
|
|
2016
Q3 | $443K | Sell |
5,595
-664
| -11% | -$53.9K | 0.07% | 108 |
|
|
2016
Q2 | $522K | Buy |
6,259
+200
| +3% | +$17.7K | 0.08% | 101 |
|
|
2016
Q1 | $557K | Buy |
6,059
+2,310
| +62% | +$208K | 0.08% | 98 |
|
|
2015
Q4 | $379K | Buy |
3,749
+1,050
| +39% | +$109K | 0.05% | 111 |
|
|
2015
Q3 | $265K | Buy |
2,699
+1,235
| +84% | +$137K | 0.04% | 128 |
|
|
2015
Q2 | $171K | Hold |
1,464
| – | – | 0.02% | 158 |
|
|
2015
Q1 | $144K | Buy |
1,464
+700
| +92% | +$71.1K | 0.02% | 175 |
|
|
2014
Q4 | $72K | Hold |
764
| – | – | 0.01% | 235 |
|
|
2014
Q3 | $81.3K | Hold |
764
| – | – | 0.01% | 226 |
|
|
2014
Q2 | $63.3K | Hold |
764
| – | – | 0.01% | 254 |
|
|
2014
Q1 | $54.1K | Hold |
764
| – | – | 0.01% | 271 |
|
|
2013
Q4 | $57.4K | Hold |
764
| – | – | 0.01% | 263 |
|
|
2013
Q3 | $48K | Hold |
764
| – | – | 0.01% | 284 |
|
|
2013
Q2 | $39.2K | Buy |
+764
| New | +$39.8K | ﹤0.01% | 303 |
|
Other funds holding GILD
VCM
VPM
Estabrook Capital Management's GILD Position: Q1 2026 in Review
Estabrook Capital Management increased its Gilead Sciences (GILD) stake by 1.3% in Q1 2026, buying an estimated $2.24K and bringing the position to 1,216 shares worth $169K. The position accounts for 0.02% of the portfolio, ranked #126.
Estabrook Capital Management first reported a position in GILD in Q2 2013 and has held it in 35 quarters since. The position peaked at $557K in Q1 2016. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Estabrook Capital Management held 1,216 shares of Gilead Sciences worth $169K as of Q1 2026.
- Estabrook Capital Management bought 16 Gilead Sciences shares in Q1 2026, an estimated $2.24K.
- Gilead Sciences made up 0.02% of Estabrook Capital Management's portfolio in Q1 2026, its #126 holding.
- Estabrook Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 35 quarters since.
- Estabrook Capital Management's Gilead Sciences position peaked at $557K in Q1 2016.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Estabrook Capital Management's 13F filing for Q1 2026, filed 14 May 2026.